A Single-Centre, Single-Administration, Dose-Escalation Study and A Single-Centre, Randomized, Open-Label, Two-cycle Crossover Food Effect Study of SKLB1028 in Healthy Subjects
Latest Information Update: 18 Nov 2021
At a glance
- Drugs SKLB 1028 (Primary)
- Indications Acute myeloid leukaemia; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors CSPC ZhongQi Pharmaceutical Technology
Most Recent Events
- 10 Nov 2021 New trial record